Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Kurt Orlofski

Mr. Kurt Orlofski

President and COO, G & W Laboratories Inc

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Kurt Orlofski, CPA, CMA, is President and COO at G & W Laboratories. Mr. Orlofski was previously, President of Wockhardt USA. Wockhardt is a global leader in pharmaceuticals and biotechnology. Previously, Mr. Orlofski was President and Chief Executive Officer of Pliva, the US subsidiary of the global specialty pharmaceutical company Pliva. He was responsible for all Pliva US businesses including USD300m of generics business. Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alpharma Human Pharmaceuticals. His areas of expertise include pharmaceutical general management, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions including integration, contract manufacturing deals in and out, and negotiation and execution of supplier and customer supply agreements. (This is me - Update Profile)


Employment History

2009 - Unspecified
President and COO, G & W Laboratories Inc
2007 - 2009
President , Wockhardt USA, Inc.
2004 - 2006
President and Chief Executive Officer, PLIVA INC.
2001 - 2004
Sr. Vice President of Global Business Development, ALPHARMA INC.

GLG NewsSM Analyses by Kurt Orlofski(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Lupin acquisition in Japan a positive

October 16, 2007

Indian Drug Maker Lupin to Acquire Kyowa Pharmaceutical | www.pipelinereview.com

Japan is the second largest generic market in the world. Kyowa Pharmaceuticals has a real presence in the Japanese pharmaceutical market. Allows Kyowa to leverage low cost Indian manufacturing while Lupin gains a large and growing market for distribution.

Leading institutions connect with Kurt Orlofski through GLG

GLG Live Meetings with Kurt Orlofski(?)

Kurt Orlofski has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare